Alnylam price target raised to $300 from $265 at Chardan

Chardan raised the firm’s price target on Alnylam to $300 from $265 and keeps a Buy rating on the shares following the Q2 report. With the clinical risk overhang for ATTR-CM now largely removed, the stock can now begin to reflect other positive data readouts being generated by the company’s pipeline, the analyst tells investors in a research note.